ADMA Biologics announced preliminary unaudited total revenue for FY 2025 of approximately $510-$511 million, meeting or exceeding prior guidance.
Year-end 2025 cash grew to approximately $88 million with an estimated operating cash flow of ~$40 million in 4Q 2025.
ADMA targets over $1.1 billion in annual revenue by FY 2029, representing around 20% CAGR.
2025 Total Revenue
Preliminary unaudited total revenue for FY 2025: $510-$511 million.
2026 Projections
FY 2026 revenue expected to be $635 million, with Adjusted Net Income of $255 million and Adjusted EBITDA of $360 million.
2027 Outlook
FY 2027 revenue projected at $775 million, with Adjusted Net Income of $315 million and Adjusted EBITDA of $455 million.
- ADMA's strategic plasma network repositioning is expected to enhance margins and supply visibility.
- ADMA targets significant revenue growth and margin expansion through yield-enhanced production and operational efficiencies.
ADMA Biologics shows strong financial performance with revenue growth and increased profitability estimates. The company's strategic initiatives position it for sustained growth and margin expansion in the coming years.